- Trials with a EudraCT protocol (64)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
64 result(s) found for: Chemotherapeutic Agent.
Displaying page 1 of 4.
EudraCT Number: 2005-001944-21 | Sponsor Protocol Number: PALO-03-14 | Start Date*: 2005-09-23 |
Sponsor Name:Helsinn Healthcare SA | ||
Full Title: Multicenter, Phase III, Open-Label, Uncontrolled Study to Assess the Safety and Efficacy of a Single Oral Dose of Palonosetron 0.75 mg in the Prevention of Chemotherapy Induced Nausea and Vomiting ... | ||
Medical condition: Moderately emetogenic chemotherapy induced nausea and vomiting | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-003075-37 | Sponsor Protocol Number: NLG-LBC-04 | Start Date*: 2004-12-20 |
Sponsor Name:Nordic Lymphoma Group | ||
Full Title: CHOEP-14 + rituximab with CNS prophylaxis in patients less than 65 years with Diffuse Large B-Cell Lymphoma/Follicular Lymphoma grade III, stage II-IV with risk factors (age adjusted IPI) ≥ 2. A ph... | ||
Medical condition: 18-64 year old patients having primary diffuse large B-cell lymphoma (DLBCL) with risk factors (age adjusted IPI≥2), or follicular lymphoma grade III | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-004278-41 | Sponsor Protocol Number: 01081 | Start Date*: 2010-04-19 |
Sponsor Name:Institut Jules Bordet | ||
Full Title: A phase II study of doxorubicin, cyclophosphamide and vindesine with valproic acid in patients with refractory or relapsing small cell lung cancer after platinum derivatives and etoposide. | ||
Medical condition: This is a prospective phase II study investigating well-known chemotherapeutic (doxorubicin, cyclophosphamide, vindesine) and antiepileptic (valproate) agents, in combination, for the treatment of... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-007827-14 | Sponsor Protocol Number: PALO-08-09 | Start Date*: 2009-11-24 | |||||||||||
Sponsor Name:Helsinn Healthcare SA | |||||||||||||
Full Title: Multicenter, Phase IV, Open-Label, Uncontrolled Study to Assess the Efficacy and Safety of a Single Intravenous Dose of Palonosetron 0.25 mg (Aloxi®, Onicit®, Paloxi®) in the Prevention of Chemothe... | |||||||||||||
Medical condition: Prevention of moderately emetogenic CINV in up to four repeated and consecutive single-day MEC cycles administered to patients with Non-Hodgkin’s Lymphomas. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001714-15 | Sponsor Protocol Number: Met.Panc.01 | Start Date*: 2013-07-23 |
Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie | ||
Full Title: Phase II trial of capecitabine (Xeloda®) + nab-paclitaxel (Abraxane®) in patients with metastatic pancreatic cancer | ||
Medical condition: metastatic pancreatic adenocarcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001783-34 | Sponsor Protocol Number: MK-0517-044 | Start Date*: 2015-08-05 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||
Full Title: A phase III, randomized, placebo-controlled clinical trial to study the efficacy and safety of MK-0517/fosaprepitant and ondansetron versus ondansetron for the prevention of chemotherapy-induced na... | ||
Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) NO (Completed) ES (Completed) LT (Completed) FI (Completed) PT (Completed) EE (Completed) HU (Completed) GB (Completed) NL (Completed) GR (Completed) Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2007-001421-10 | Sponsor Protocol Number: 4783-08 | Start Date*: 2008-09-06 | |||||||||||
Sponsor Name:Synta Pharmaceuticals Corp. | |||||||||||||
Full Title: A Randomized, Double-Blind, Phase III Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects with Stage IV Metastatic Melanoma | |||||||||||||
Medical condition: Stage IV Metastatic Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Prematurely Ended) GB (Prematurely Ended) CZ (Ongoing) IT (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006478-79 | Sponsor Protocol Number: SX-PHCC-001 | Start Date*: 2007-07-16 | |||||||||||
Sponsor Name:SIRTEX Medical Europe | |||||||||||||
Full Title: Study of Radioembolization (RE) with SIR-Spheres® versus Transarterial Chemoembolisation (TACE) in patients with unresectable primary Hepatocellular Carcinoma. A comparative, prospective, randomise... | |||||||||||||
Medical condition: Unresectable primary hepatocellular carcinoma (pHCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001094-15 | Sponsor Protocol Number: CDBC1 | Start Date*: 2006-09-04 |
Sponsor Name:Oxford Radcliffe Hospitals NHS Trust (Cancer Research UK Medical Oncology Unit, Churchill Hospital) | ||
Full Title: Dose-banding of carboplatin: Effect on area under the plasma concentration - time curve (AUC) compared with individualised dosing | ||
Medical condition: Conditions for which carboplatin is indicated for: 1. Advanced ovarian carcinoma of epithelial origin in: - first line therapy - second line therapy, after other treatments have failed. 2. Small ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000137-37 | Sponsor Protocol Number: PALO-03-13 | Start Date*: 2005-09-23 |
Sponsor Name:Helsinn Healthcare SA | ||
Full Title: Single Dose, Randomized, Double-Blind, Parallel Group, Multicenter Study of Palonosetron 0.25 mg, 0.50 mg and 0.75 mg Administered by the Oral Route versus Palonosetron 0.25 mg IV for the Preventio... | ||
Medical condition: Moderately emetogenic chemotherapy induced nausea and vomiting | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001862-84 | Sponsor Protocol Number: ISO-CC-005 | Start Date*: 2014-07-24 | |||||||||||
Sponsor Name:Isofol Medical AB | |||||||||||||
Full Title: An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin®) in Combination with a Fixed Dose of 5-Fluorouracil (5-FU) alone or together with a Fi... | |||||||||||||
Medical condition: Advanced metastatic colorectal cancer (stage IV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) NO (Prematurely Ended) DK (Prematurely Ended) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002313-41 | Sponsor Protocol Number: CRC2021-02 | Start Date*: 2023-06-06 | ||||||||||||||||
Sponsor Name:CENTRO RICERCHE CLINICHE DI VERONA | ||||||||||||||||||
Full Title: A PHASE 2, MULTICENTER, OPEN LABEL, CLINICAL TRIAL EVALUATING SAFETY AND ACTIVITY OF NIVOLUMAB/IPILIMUMAB AND CHEMOTHERAPY COMBINATION IN ADVANCED NSCLC PATIENTS WITH HIV, HBV, HCV AND POST-ACUTE S... | ||||||||||||||||||
Medical condition: advanced non-small-cell lung cancer (NSCLC) (both squamous and non-squamous) in patients with chronic viral infections or sequalae from Sars-Cov2 infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000907-27 | Sponsor Protocol Number: D2782C00010 | Start Date*: 2008-10-24 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety and Pharmacokinetics of AZD4877 Administered Weekly in Patients with Recurrent Advanced Ur... | ||
Medical condition: Stage IV urothelial Cancer Cáncer de urotelio estadío 4 | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: ES (Completed) DE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-003003-39 | Sponsor Protocol Number: 06/075 | Start Date*: 2006-08-10 |
Sponsor Name:Academic Medical Center | ||
Full Title: Methotrexate versus expectant management in women with ectopic pregnancy (METEX study) | ||
Medical condition: Women with an ectopic pregnancy with low but plateauing serum hCG concentrations. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001852-38 | Sponsor Protocol Number: EFC10203 | Start Date*: 2007-12-21 | |||||||||||
Sponsor Name:sanofi-aventis recherche & developpement | |||||||||||||
Full Title: A Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of S-1 as a Single Agent at 30 mg/m2 BID versus 5-FU Bolus Infusion for the Treatment of Patients with Metastatic Panc... | |||||||||||||
Medical condition: Advanced Pancreatic Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Completed) SE (Completed) GR (Completed) DK (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003855-11 | Sponsor Protocol Number: 025/05 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Klinikum Großhadern, University of Munich / Medical Director: Prof. Dr. med. Burkhard Götze | |||||||||||||
Full Title: Gemcitabine and cisplatin in combination with hyperthermia in patients with locally advanced or metastatic pancreatic cancer as second-line therapy after adjuvant or first-line chemotherapy with Ge... | |||||||||||||
Medical condition: Combination of standard chemotherapy with Gemcitabine and Cisplatin and regional hyperthermia in patients with locally advanced or metastatic pancreatic cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Restarted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001588-78 | Sponsor Protocol Number: SPON CU 125 | Start Date*: 2005-06-13 | |||||||||||
Sponsor Name:Cardiff University | |||||||||||||
Full Title: AML16 Pilot Trial: A Phase1/2 Trial to assess the feasibility of combining Clofarabine with daunorubicin and Daunorubicin + Clofarabine with Mylotarg in older patients with Acute Myeloid Leukaemia ... | |||||||||||||
Medical condition: Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004726-91 | Sponsor Protocol Number: 01063 | Start Date*: 2009-02-09 | |||||||||||
Sponsor Name:CHRU de Lille | |||||||||||||
Full Title: A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-smal... | |||||||||||||
Medical condition: Unresectable non metastatic stage III non small cell lung carcinoma eligible for concomitant radiochemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005395-34 | Sponsor Protocol Number: CTC-cDDP | Start Date*: 2013-04-25 |
Sponsor Name:Erasmus MC | ||
Full Title: Prospective evaluation of the predictive value of a circulating tumor cell (CTC) sensitivity profile to Cisplatin chemotherapy in metastatic breast cancer patients | ||
Medical condition: Metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004713-18 | Sponsor Protocol Number: 01061 | Start Date*: 2006-11-23 | |||||||||||
Sponsor Name:European Lung Cancer Working Party | |||||||||||||
Full Title: A phase II study assessing the curative effect of the combination of lobectomy followed by mediastinal concomitant radiochemotherapy in patients with locally advanced unresectable stage III non-sma... | |||||||||||||
Medical condition: This phase II study aim to determine if radical radiochemotherapy on the mediastinum after lobectomy can be associated with significant long term survival in patients with initially unresectable st... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.